Answers are grounded in this paper and cite their sources.
Randomized trial compares the efficacy of NB-UVB phototherapy and cyclosporine in chronic urticaria, suggesting comparable outcomes.
Background Cyclosporine is currently recommended as a third‐line therapy for chronic spontaneous urticaria (CSU), while narrowband ultraviolet B (NB‐UVB) phototherapy has shown promise. Objective To compare the efficacy and safety of NB‐UVB phototherapy versus cyclosporine in antihistamine‐refractory CSU. Methods This randomized, prospective, non‐inferiority study recruited 50 patients with antihistamine‐refractory CSU. Participants received either NB‐UVB (thrice weekly) or cyclosporine (3 mg/kg/day) for 90 days alongside maximum‐regulated doses of antihistamines, with a post‐treatment follow‐up of 90 days. The primary outcome was the Urticaria Activity Score over 7 days (UAS7), with secondary outcomes including Urticaria Control Test (UCT), Chronic Urticaria Quality of Life (CU‐QoL), and biomarkers such as IL‐6 and IL‐31. Results Both treatments significantly reduced UAS7 by Day 15. NB‐UVB provided sustained symptom control post‐treatment, while cyclosporine achieved rapid relief but led to rebound flares upon discontinuation. The non‐inferiority test showed that NB‐UVB was not significantly worse than cyclosporine for UAS7 reduction. Both therapies reduced serum IgE, with IL‐6 and IL‐31 significantly decreasing in the cyclosporine group. Limitations Single‐center design, short follow‐up duration. Conclusions NB‐UVB phototherapy is an effective and well‐tolerated alternative to cyclosporine for antihistamine‐refractory CSU, offering sustained disease suppression post‐treatment. Further research is needed to explore long‐term outcomes and broader applicability. Trial Registration Clinical Trials Registry of India: CTRI/2022/11/047799
No takes yet. Share an insight, caveat, or question.
Roshini et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: